The World Well being Group mentioned on Monday it expects Bharat Biotech to supply extra info on its COVID-19 vaccine in an extra setback to the corporate’s hopes of getting an emergency-use itemizing for the shot.
With out WHO’s nod the two-dose Covaxin is unlikely to be accepted as a sound COVID-19 vaccine around the globe. Bharat Biotech has been pursuing a WHO emergency-use itemizing for a number of months, having submitted information on a rolling foundation since July.
“We’re conscious that many individuals are ready for WHO’s advice for (Bharat Biotech’s) Covaxin to be included within the #COVID19 Emergency Use Itemizing, however we can’t minimize corners,” WHO mentioned on Twitter.
We’re conscious that many individuals are ready for WHO’s advice for Covaxin to be included within the #COVID19 Emergency Use Itemizing, however we can’t minimize corners – earlier than recommending a product for emergency use, we should consider it totally to verify it’s secure and efficient. pic.twitter.com/GDx8GAc1KU
— World Well being Group (WHO) (@WHO) October 18, 2021
Bharat Biotech didn’t instantly reply to a Reuters request for remark.
Covaxin is likely one of the three accepted vaccines which have been utilized in India for the nation’s vaccination drive for adults. Round 30% of about 944 million eligible adults have been absolutely vaccinated to this point, which incorporates the administration of greater than 112 million doses of Covaxin.
“Bharat Biotech … has been submitting information to WHO on a rolling foundation and WHO specialists have reviewed these information. WHO is anticipating one extra piece of knowledge from the corporate right now,” the worldwide well being company mentioned on Twitter.
WHO’s chief scientist Soumya Swaminathan mentioned on Sunday the company’s technical advisory group will meet on Oct. 26 to think about the itemizing for Covaxin.